Pharma M&A Advisory · MENA Region
HAYAKIL CONSULTING

Where Pharma Strategy Meets Deal Certainty

Reviving Potential. Building Futures.

Hayakil Consulting provides end-to-end advisory for pharmaceutical mergers, acquisitions, brand licensing, manufacturing assets, field force effectiveness, and public affairs — backed by 55+ combined years of senior pharma leadership across Egypt, the Gulf, and 42 MEA markets.

Our Services Schedule a Consultation
55+
Combined Years
Pharma Leadership
42
MEA Markets
Coverage
3
National
Policies Shaped
About Hayakil

Built on Pharma Intelligence,
Driven by Regional Depth

Hayakil Consulting was founded by two senior practitioners who have spent their careers inside the pharmaceutical industry — leading P&L operations at multinationals like Novartis and GlaxoSmithKline, structuring brand acquisitions, navigating regulatory environments across 42 MEA markets, and sitting at the table when governments and global pharma companies set policy together.

We operate at the intersection of scientific rigour and commercial strategy. Whether you are a multinational seeking regional entry through acquisition, a local manufacturer looking to unlock the value of your brand portfolio, a private equity firm conducting sector diligence, or an organisation seeking to shape the regulatory and policy environment in which pharmaceutical commerce takes place — we provide the analytical depth and relationship capital to inform decisive action.

Our presence in Dubai, Cairo, and Riyadh gives us the operational reach and cultural fluency to navigate the regulatory, commercial, and governmental dimensions that ultimately determine deal outcomes in this region.

Operator Credibility
Our principals have held senior executive roles inside pharmaceutical multinationals — not just advised them. We understand what acquirers need because we have been acquirers ourselves.
Regional Intelligence
Deep regulatory, commercial, and government-relations expertise across Egypt, Saudi Arabia, and the UAE — markets with distinct dynamics that demand local fluency.
Policy Influence
We have authored national healthcare policies, shaped pharmaceutical marketing codes, and architected industry-government investment frameworks — giving our clients privileged insight into the regulatory directions that govern their markets and deals.
Confidential by Design
Client engagements are ring-fenced with investment-grade discretion. All processes are governed by strict information barriers and bespoke confidentiality agreements.
Offices
Dubai, UAE
Cairo, Egypt
Riyadh, Saudi Arabia
What We Do

Advisory Services

Six disciplines across the full pharmaceutical value chain — from deal origination and due diligence through field force effectiveness and public affairs. One advisory firm, consistently principal-led.

01
Mergers & Acquisitions
Full-cycle buy-side and sell-side M&A advisory — covering target identification, valuation, negotiation, and deal structuring across MENA markets. Every assessment includes the commercial infrastructure of the target: field operations maturity, distribution depth, and HCP coverage quality are evaluated as value drivers and gap indicators.
Buy-side advisorySell-side mandateDeal structuringValuation
02
Brand Acquisition & Licensing
Strategic assessment and transaction support for the acquisition or licensing of pharmaceutical brands — including market exclusivity analysis, lifecycle positioning, and commercial valuation. For brands entering a new market or new owner, we provide the field deployment strategy: HCP prioritisation, territory architecture, and the commercial framework that drives the fastest revenue ramp.
Brand valuationIn-licensingOut-licensingMarket exclusivity
03
Manufacturing Asset Transactions
Advisory for the acquisition or divestiture of pharmaceutical manufacturing facilities — covering GMP compliance assessment, capacity utilisation, and regulatory transfer strategy. Where a facility comes with a commercial product portfolio, the field force and distribution infrastructure are assessed as integral components of asset value.
Facility acquisitionGMP assessmentCapacity analysisTech transfer
04
Due Diligence & Commercial Excellence
Comprehensive multi-stream due diligence for acquirers, investors, and lenders evaluating pharmaceutical targets across MENA — covering commercial, regulatory, scientific, and operational dimensions. Our commercial excellence stream goes beyond the financials:
  • Field force audit: HCP segmentation rigour, territory coverage quality, call productivity, and representative capability — benchmarked against MENA sector norms
  • CRM maturity: platform utilisation, data quality, KPI framework, and the gap between system capability and actual adoption
  • Commercial gap pricing: each identified weakness is translated into a post-acquisition investment requirement and a corresponding deal-price adjustment
  • Regulatory & scientific streams: dossier status, registration timelines, GMP compliance, IP landscape, and pharmacovigilance integrity across Egypt, Saudi Arabia, UAE, and 42 MEA markets
Commercial DDRegulatory DDScientific DDField force auditCRM assessment
05
Strategic Partnerships & JVs
Structuring and negotiation of pharmaceutical joint ventures, co-promotion agreements, and strategic alliances across MENA — including track record spanning multinational-government investment agreements aligned with Saudi Vision 2030. Our work covers the full partnership lifecycle:
  • Deal architecture: JV structures, co-promotion frameworks, licensing agreements, and toll-manufacturing arrangements tailored to each partner's regulatory and commercial position
  • Field alignment: for co-promotion mandates, we design territory demarcation, shared CRM protocols, HCP coverage responsibilities, and performance frameworks that protect both partners' commercial interests and eliminate channel conflict
  • Government partnerships: strategic investment agreement structuring with national authorities, aligning multinational capabilities with Vision 2030 priorities and national manufacturing agendas
JV structuringCo-promotionField alignmentMarket entryVision 2030
06
Public Affairs & Policy Engagement
The most consequential pharmaceutical decisions are often made in ministries, not boardrooms. Hayakil provides sophisticated public affairs counsel to companies and industry bodies seeking to shape the environment in which they operate.
  • Policy shaping: marketing codes, regional HQ frameworks, and healthcare legislation — informed by outcomes adopted at government decree level
  • Strategic alliances: industry-government investment agreements aligned with Vision 2030 and national manufacturing agendas
  • Trade association & advocacy: active GCC and MENA representation within ethical and legal boundaries; regulatory horizon-scanning for shifts affecting deal viability
Policy shapingMarketing codesMoH · SFDA · EDATrade associationsCompliant advocacy
Commercial Operations

Field Force Effectiveness

A pharmaceutical field force without a rigorous effectiveness strategy is the industry's most expensive underperforming asset. Hayakil provides end-to-end field force advisory — from strategy design through CRM optimisation and precision HCP targeting — translating field investment into measurable market impact across MENA.

I
Strategy & Go-to-Market Design

Field force sizing, structure, and go-to-market model aligned to brand lifecycle stage, competitive dynamics, and therapeutic area norms across MENA — setting the strategic foundation before any deployment decision is made.

II
Target Audience & HCP Segmentation

Physician and pharmacist segmentation by prescribing behaviour, influence tier, and channel preference — enabling precision targeting over broad-reach detailing and directing field effort toward the HCPs who drive disproportionate market share.

III
Reach & Coverage Optimisation

Territory design and call planning to maximise high-value HCP coverage while eliminating non-productive frequency — built on local market access intelligence and competitive coverage benchmarking.

IV
CRM Strategy & Optimisation

Platform selection, data architecture design, KPI framework development, and adoption programmes that transform CRM from an administrative burden into a commercial intelligence engine driving measurable market share improvement.

V
Performance Measurement & Analytics

Effectiveness dashboards, call quality frameworks, and productivity benchmarking against regional and global pharmaceutical norms — giving management the visibility to intervene early and reallocate effort toward highest-return activities.

VI
Capability Building

Field manager coaching frameworks, representative training design, and incentive structure alignment to commercial objectives — ensuring strategic intent translates into consistent field execution across every territory.

Our Process

360° Due Diligence Framework

Acquiring a pharmaceutical asset without deep due diligence is the fastest path to value destruction. Our structured process leaves no dimension unexamined.

I
Commercial & Market Due Diligence
Market sizing, competitive landscape, pricing sustainability, distribution access, and revenue quality assessment across target geographies.
II
Regulatory & Dossier Due Diligence
Review of marketing authorisations, dossier status, registration timelines, renewal risks, and regulatory authority relationships across Egypt, Saudi Arabia, UAE, and 42 MEA markets.
III
Scientific & Technical Due Diligence
Formulation analysis, manufacturing process review, IP and patent landscape, bioequivalence data, pharmacovigilance integrity, and quality architecture.
IV
Operational & GMP Due Diligence
Facility inspection readiness, GMP compliance history, capacity headroom, CAPEX requirements, and supply chain resilience for manufacturing assets.
V
Policy & Regulatory Environment Assessment
Horizon-scanning for regulatory and policy change, assessment of government-relations risk to asset valuation, and evaluation of the target company's standing with ministries and regulatory authorities — including pending policy shifts that could affect commercial projections or deal structure.
VI
Financial Modelling & Valuation
DCF modelling, comparable transaction benchmarking, royalty rate analysis, and post-acquisition integration cost estimation to establish defensible deal parameters.
What Our Reports Deliver
  • Investable opportunity assessment with a clear go/no-go recommendation
  • Identified material risks with probability and impact ratings
  • Regulatory pathway analysis and authority relationship map
  • Policy and regulatory horizon assessment — pending changes affecting commercial projections or deal structure
  • Government-relations risk profile of the target and its standing with relevant authorities
  • Comparable deal benchmarks from regional and global transactions
  • Valuation range with supporting assumptions and sensitivities
  • Integration or licensing commercialisation roadmap
  • Conditions precedent and deal structuring recommendations
  • Executive summary formatted for investment committee presentation
Our Principals

The Team Behind the Advice

Hayakil is led by two senior practitioners whose combined experience spans more than 55 years of pharmaceutical operations, regulatory affairs, business development, M&A, and government relations and policy design across the MENA region.

Hatem Hammad
Hatem
Hammad
Founder &
Principal Consultant
Dubai & Cairo
LinkedIn ›

Hatem brings over 30 years of international experience in pharmaceutical general management, business development, and M&A across the MENA region. His career spans senior P&L leadership at Novartis Consumer Health — where he doubled regional revenue over five years as Operating Unit Head for the Middle East, Iran, and Pakistan — through to Galderma, where he achieved 35%+ year-on-year OTC growth across 60 new product introductions, and Nestlé Health Science, where he led full business operations across the Coastal Arabia cluster.

He has led end-to-end M&A due diligence on transactions exceeding $100 million, acquired a local consumer brand generating over $10 million within three years, and founded MODAWA LLC — the first Total Parenteral Nutrition compounding facility outside a hospital in the Middle East, achieving swift regulatory approval.

Pharmaceutical M&A, brand acquisition, and financial due diligence
P&L leadership across OTC, consumer health, and nutrition (Novartis, Galderma, Nestlé)
Field force effectiveness, commercial strategy, and CRM-driven market optimisation
Legal entity setup, supply chain, and operational turnaround across Egypt, UAE, and Saudi Arabia
Dr. Othman Al-Mutlaq
Dr. Othman
Al-Mutlaq
Co-Founder &
Principal Consultant
Riyadh
LinkedIn ›

Dr. Othman Al-Mutlaq brings over 25 years of senior pharmaceutical leadership across regulatory affairs, corporate affairs, and government relations — spanning Novartis and GlaxoSmithKline, a founding regulatory role at Tabuk Pharmaceutical Industries, and a formative period as Technical Registration Committee Secretary at Saudi Arabia's Ministry of Health, where he served on the MoH Legislation Committee across multiple pharmaceutical guidelines.

At Novartis, he spent 23 years growing from Scientific Regulatory Manager to Head of Corporate Affairs for MEA — building the regional regulatory infrastructure across 42 markets, authoring three major national healthcare policies, architecting a landmark strategic investment agreement between Novartis Global and the Saudi Government, and leading the development of pharmaceutical marketing codes and regional HQ frameworks subsequently adopted at government decree level.

Pharma M&A deal structuring, regulatory due diligence, and partnership frameworks
Regulatory affairs across 42 MEA markets — SFDA, EDA, GCC, EU/US frameworks
Government relations, healthcare policy design, and MoH legislation engagement
Pharmaceutical marketing codes, regional HQ frameworks, and industry-government investment agreements
Trade association leadership, compliant advocacy, and multi-stakeholder coalition building
Focus Areas

Pharmaceutical Sectors We Serve

Generic & Branded Generic Pharmaceuticals ›
OTC, Consumer Health & Nutraceuticals ›
Specialty & Hospital Pharmaceuticals ›
Manufacturing Facilities & CMOs ›
Veterinary Pharmaceuticals ›
Pharmaceutical Distribution & Logistics ›
Generic & Branded Generic Pharmaceuticals

The MENA generics market is one of the highest-growth pharmaceutical segments in the world. We advise on the acquisition of generic brand portfolios, licensing of molecules from originator companies, and the evaluation of regional generics manufacturers as acquisition targets.

  • Brand acquisition from multinational originators post-patent expiry
  • In-licensing of molecules for MENA registration and commercialisation
  • Acquisition of local generics manufacturers with established distribution
  • Competitive pricing and market share analysis for valuation support
Why Hayakil

What Sets Us Apart

⬡
Operators, Not Just Advisors

Our principals have run P&Ls, built distribution networks, launched manufacturing facilities, and closed deals inside major pharmaceutical organisations. We advise from experience, not theory.

◈
Scientific + Commercial Duality

Our founding team combines pharmaceutical science and regulatory credentials with commercial and financial advisory skills — eliminating the gap between technical diligence and deal-making judgement.

◉
Policy Architects

We have not merely navigated regulatory environments — we have helped design them. Our ability to engage governments, shape pharmaceutical codes, and construct the frameworks that govern industry commerce is a capability that few advisors anywhere can credibly claim.

◈
Commercial Transformation

Beyond transactions, we help pharmaceutical companies maximise the commercial performance of the assets they already hold — through field force strategy, CRM optimisation, and precision HCP targeting that drives measurable market share improvement.

◇
Principal-Led at Every Stage

Clients work directly with Hatem and Dr. Othman — not delegated to junior analysts. The experience you engage is the experience that delivers your work, from first brief to final report.

Get in Touch

Begin a Conversation

Whether you are evaluating a specific target, preparing an asset for sale, seeking a strategic partner for market entry, navigating a government affairs challenge, or looking to transform your field force commercial effectiveness — our first conversation is always confidential and without obligation.

General Enquiries
[email protected]
Hatem Hammad — Dubai & Cairo
[email protected]
Dr. Othman Al-Mutlaq — Riyadh
[email protected]
Website
www.hayakillc.com
Submitting will open your email client with a pre-filled message to [email protected] — no third-party service required.